Ontology highlight
ABSTRACT:
SUBMITTER: Younes A
PROVIDER: S-EPMC6553835 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
Younes Anas A Sehn Laurie H LH Johnson Peter P Zinzani Pier Luigi PL Hong Xiaonan X Zhu Jun J Patti Caterina C Belada David D Samoilova Olga O Suh Cheolwon C Leppä Sirpa S Rai Shinya S Turgut Mehmet M Jurczak Wojciech W Cheung Matthew C MC Gurion Ronit R Yeh Su-Peng SP Lopez-Hernandez Andres A Dührsen Ulrich U Thieblemont Catherine C Chiattone Carlos Sergio CS Balasubramanian Sriram S Carey Jodi J Liu Grace G Shreeve S Martin SM Sun Steven S Zhuang Sen Hong SH Vermeulen Jessica J Staudt Louis M LM Wilson Wyndham W
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20190322 15
<h4>Purpose</h4>Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non-germinal center B-cell DLBCL.<h4>Patients and methods</h4>Patients were randomly assigned at a one-to-one ratio to ibrutinib (560 mg per day orally) plus R-CHOP or placebo plus R-CHOP. The primary end point was event-free surviv ...[more]